Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma.

Tanguy Y SeiwertSophie WildsmithJérôme FayetteKevin HarringtonMaura GillisonMyung-Ju AhnShunji TakahashiJared WeissJean-Pascal MachielsShrujal BaxiValerie BakerBrent EvansNassim Morslinull Jill WalkerKatia RealAnne L'HernaultAmanda Psyrri

Published in: Cancer immunology, immunotherapy : CII (2024)

bTMB demonstrated potential utility for selecting patients with R/M HNSCC who benefited from durvalumab with or without tremelimumab versus EXTREME. Trial registration ClinicalTrials.gov identifier NCT02551159.

Keyphrases

small cell lung cancer
squamous cell carcinoma
clinical trial
study protocol
climate change
phase iii
randomized controlled trial
type diabetes
phase ii
metabolic syndrome
risk assessment
adipose tissue
insulin resistance
open label